Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Rises By 278.0%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 396,100 shares, an increase of 278.0% from the October 15th total of 104,800 shares. Based on an average trading volume of 252,700 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.9% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Raymond James decreased their price target on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Friday, November 8th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xilio Therapeutics stock. Renaissance Technologies LLC lifted its position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 295,000 shares of the company’s stock after purchasing an additional 45,554 shares during the period. Renaissance Technologies LLC owned 0.80% of Xilio Therapeutics worth $280,000 at the end of the most recent quarter. 54.29% of the stock is currently owned by institutional investors and hedge funds.

Xilio Therapeutics Stock Performance

Shares of NASDAQ XLO opened at $1.08 on Wednesday. The stock has a market cap of $47.47 million, a price-to-earnings ratio of -0.62 and a beta of -0.24. Xilio Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $1.93. The firm’s 50-day simple moving average is $0.89 and its 200 day simple moving average is $0.95.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.